| |
Impulsivity (n = 34) |
Apathy
(n = 24) |
Control
(n = 36) |
Statistic
3-group comparisons
(ANOVA / Kruskall-Wallis or chi-square |
| Mean (SD); *median (for non-normal data) |
| Age at assessment |
58.65 (9.09) |
69.92 (6.91) |
62.33 (11.14) |
F=10.12,p<.001
‡‡‡† |
| Age at onset of motor PD (years) |
50.85 (8.84) |
59.96 (9.99) |
55.44 (12.91) |
F=5.02,p=.009
‡‡ |
| *Disease duration
(months) |
91.76 (44.91);
90.00 |
125.00 (82.81);
96.00 |
76.06 (60.11);
60.00 |
H(2)=8.02, p=.02
#†† |
| UPDRS1motor |
26.87 (10.13) |
37.42 (11.79) |
23.65 (10.51) |
F=12.12,p<.001
‡‡ ††† |
| *UPDRS1 complications |
4.62 (3.33);
4.00 |
3.79 (3.47);
3.00 |
2.72 (3.07);
1.50 |
H(2)=7.85, p=.02
## |
| *Hoehn-Yahr stage |
2.21 (0.72);
2.00 |
2.63 (0.73);
3.00 |
2.19 (0.65);
2.00 |
H(2)=6.95, p=.03
‡ † |
| *Levo-dopa daily equivalents (LEDD)2 |
988.27
(592.93);
843.46 |
790.14
(507.08);
706.98 |
679.70 (608.63);
627.44 |
H(2)=7.39, p=.03
#‡ (trend) |
| *Levo-dopa daily equivalents, DA agonists only (DA-LEDD)2 |
243.16
(161.24) |
223.45
(59.52) |
257.98
(162.71) |
F(2)=.174, p=.841 |
| *HADS3 anxiety subscale |
8.47 (4.34);
8.50 |
5.96 (4.02);
5.50 |
4.29 (3.26);
3.00 |
H(2)=18.16, p<.001
###‡† |
| *HADS3 depression subscale |
6.18 (3.14);
6.50 |
9.13 (3.43);
10.00 |
4.03 (2.84);
3.00 |
H(2)=26.06, p<.001
##‡‡††† |
| BIS-II4 |
61.85 (16.82) |
57.6 (9.54) |
51.40 (15.40) |
F=4.25;p=.01
# |
| *AES-C5
Total score |
25.03 (11.52);
19.00 |
46.21 (12.24); 44.00 |
21.75 (4.87);
19.50 |
H(2)=42.23; p<.001
‡‡‡††† |
|
